These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 4884753)

  • 21. [Management of multiple sclerosis].
    Jerusalem F
    Schweiz Med Wochenschr; 1968 Nov; 98(48):1907-8. PubMed ID: 4303139
    [No Abstract]   [Full Text] [Related]  

  • 22. The antispastic effects of Ba 34647 (B-4-p-chlorophenyl-gamma-amino-butyric acid) a GABA derivative.
    Lapierre YD; Elie R; Tetreault L
    Curr Ther Res Clin Exp; 1974 Oct; 16(10):1059-68. PubMed ID: 4154825
    [No Abstract]   [Full Text] [Related]  

  • 23. [Study of the H reflex in spastic subjects treated with a GABA derivative (Ciba 34647-BA)].
    Fra L; Bergamini L; Brignolio F; Delsedime M
    Riv Neurol; 1971; 41(3):152-60. PubMed ID: 5126432
    [No Abstract]   [Full Text] [Related]  

  • 24. ["The largest snapshot of multiple sclerosis". Interferons compared].
    MMW Fortschr Med; 2003 Jun; 145(24):55. PubMed ID: 12866307
    [No Abstract]   [Full Text] [Related]  

  • 25. Gaba derivative in spasticity. (Beta-(4-chlorophenyl)-gamma-aminobutyric acid, Ciba 34.647-Ba).
    Pedersen E; Arlien-Soborg P; Grynderup V; Henriksen O
    Acta Neurol Scand; 1970; 46(3):257-66. PubMed ID: 4918508
    [No Abstract]   [Full Text] [Related]  

  • 26. MaxEPA in multiple sclerosis.
    French JM
    Br J Clin Pract Suppl; 1984; 31():117-21. PubMed ID: 6091716
    [No Abstract]   [Full Text] [Related]  

  • 27. Diazepam in the treatment of spasticity. A preliminary quantitative evaluation.
    Evine IM; Jossmann PB; Friend DG; DeAngelis V; Kane M
    J Chronic Dis; 1969 Jun; 22(1):57-62. PubMed ID: 5794241
    [No Abstract]   [Full Text] [Related]  

  • 28. A multiple sclerosis therapy?
    Waksman BH
    Nature; 1987 Aug 20-26; 328(6132):664-5. PubMed ID: 3302729
    [No Abstract]   [Full Text] [Related]  

  • 29. [Statistical analysis of the results obtained with prolonged treatment with gamma-amino-beta-hydroxybutyric acid of character disorders].
    Ferro-Milone F; Toschi P; Lorizio A
    Riv Neurobiol; 1966; 12(3):267-97. PubMed ID: 4860044
    [No Abstract]   [Full Text] [Related]  

  • 30. [About the article: "Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis" by Jacobs LD et al].
    Labetouelle M
    J Fr Ophtalmol; 2001 Feb; 24(2):222. PubMed ID: 11332406
    [No Abstract]   [Full Text] [Related]  

  • 31. Diazepam in the relief of muscle spasm resulting from spinal-cord lesions.
    Neill RW
    Ann Phys Med; 1964; Suppl():33-8. PubMed ID: 5825181
    [No Abstract]   [Full Text] [Related]  

  • 32. [Effect of neurolax on spasticity in the light of clinical observations].
    Weiss M; Kiwerski J; Rudnicki S; Jedrychowska K
    Pol Tyg Lek; 1969 Jul; 24(28):1095-6. PubMed ID: 4896580
    [No Abstract]   [Full Text] [Related]  

  • 33. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH
    Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early treatment of multiple sclerosis to prevent neurologic damage.
    Coyle PK
    Neurology; 2008 Dec; 71(24 Suppl 3):S3-7. PubMed ID: 19064872
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EMG phenomena in the "stiff-man" syndrome.
    Ricker K; Mertens HG
    Electroencephalogr Clin Neurophysiol; 1968 Oct; 25(4):413. PubMed ID: 4176620
    [No Abstract]   [Full Text] [Related]  

  • 36. [Gammalon in the rehabilitation in infantile cerebral palsy].
    Gershman RN; Vasilenko MA; Iliushina GG; Iakimenko GD; Iakovleva SM
    Pediatr Akus Ginekol; 1977 Dec; (6):26-7. PubMed ID: 343053
    [No Abstract]   [Full Text] [Related]  

  • 37. Expanded clinical trials of treatments for multiple sclerosis. The Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis of The National Multiple Sclerosis Society.
    Whitaker JN
    Ann Neurol; 1993 Dec; 34(6):755-6. PubMed ID: 8250523
    [No Abstract]   [Full Text] [Related]  

  • 38. [Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis].
    Wissel J; Entner T
    Wien Klin Wochenschr; 2001; 113 Suppl 4():20-4. PubMed ID: 15506048
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Double-blind study of metaxalone; use as skeletal-muscle relaxant.
    Diamond S
    JAMA; 1966 Feb; 195(6):479-80. PubMed ID: 5951838
    [No Abstract]   [Full Text] [Related]  

  • 40. Use of diazepam for the relief of spasticity in multiple sclerosis.
    Simpson CA
    Ann Phys Med; 1964; Suppl():39-40. PubMed ID: 5825182
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.